Merck KGaA Joins Race To Develop Next-Gen PARP Inhibitors
Links Up With Italy’s Nerviano
Executive Summary
PARP inhibitors have had great success in treating a number of cancers but the German major has placed a $65m bet that Nerviano's selective PARP1 approach could produce a safer and more efficacious option.
You may also be interested in...
Deal Watch: GSK Gets Rights To Spero’s Phase III Antibiotic
GSK takes equity stake in Spero, and global rights to tebipenem except for certain Asian markets. Merck KGaA gets rights to Nerviano’s next-generation PARP inhibitor for cancer.
Artios On How To Strike A Deal With Big Pharma
With the number of deals being inked in biopharma continuing apace, the UK firm spoke to Scrip about how to negotiate the line between what big pharma wants and what a biotech is likely to get.
Partner Or Go It Alone? TG Therapeutics Ponders EU Plans For Briumvi
TG Therapeutics has successfully launched Briumvi on its own in the US, despite fierce competition from established same-class MS drugs Ocrevus and Kesimpta, but is still weighing up the pros and cons of partnering for the European market.